Propensity-Matched Comparison of Evolut-R Transcatheter Aortic Valve Implantation With Surgery in Intermediate-Risk Patients (from the SURTAVI Trial)
The Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) trial demonstrated the noninferiority of transcatheter aortic valve implantation (TAVI) using a self-expanding bioprosthesis to surgical aortic valve replacement (SAVR) for the primary end point of all-cause mortality or disabling stroke at 2 years in patients with severe, symptomatic aortic stenosis at intermediate risk for surgery.1 The majority of TAVI patients in the SURTAVI trial (84%) received the first generation CoreValve bioprosthesis (Medtronic, Minneapolis, Minnesota).
Source: The American Journal of Cardiology - Category: Cardiology Authors: Steven J. Yakubov, Nicolas M. Van Mieghem, Michael J. Reardon, Patrick W. Serruys, Hemal Gada, Mubashir Mumtaz, G. Michael Deeb, Susheel Kodali, Isaac George, Stephan Windecker, Neal Kleiman, Stanley J. Chetcuti, Carlos Sanchez, Harold L. Dauerman, Shuzhe Source Type: research